BEV-IP: Perioperative chemotherapy with bevacizumab in patients undergoing cytoreduction and intraperitoneal chemoperfusion for colorectal carcinomatosis

Wouter Willaert, Kurt Van Der Speeten, Gabriel Liberale, Wim Ceelen, Wouter Willaert, Kurt Van Der Speeten, Gabriel Liberale, Wim Ceelen

Abstract

Background: Selected patients with peritoneal carcinomatosis (PC) from colorectal cancer (CRC) benefit from cytoreductive surgery (CRS) combined with intraperitoneal chemoperfusion (IPC). However, even after optimal cytoreduction, systemic and locoregional recurrence are common. Perioperative chemotherapy with bevacizumab (BEV) may improve the outcome of these patients.

Methods/design: The BEV-IP study is a phase II, single-arm, open-label study aimed at patients with colorectal or appendiceal adenocarcinoma with synchronous or metachronous PC. This study evaluates whether perioperative chemotherapy including BEV in combination with CRS and oxaliplatin-based IPC results in acceptable morbidity and mortality (primary composite endpoint). Secondary endpoints are treatment completion rate, chemotherapy-related toxicity, pathological response, progression free survival, and overall survival.

Discussion: The BEV-IP trial is the first prospective assessment of the safety and efficacy of perioperative chemotherapy combined with anti-angiogenic treatment in patients undergoing CRS and IPC for colorectal peritoneal metastases.

Trial registration: ClinicalTrials.gov Identifier: NCT02399410 EudraCT number: 2015-001187-19 (registered March 9, 2015).

Figures

Fig. 1
Fig. 1
Flowchart of the BEV-IP study

References

    1. Herszenyi L, Tulassay Z. Epidemiology of gastrointestinal and liver tumors. Eur Rev Med Pharmacol Sci. 2010;14(4):249–258.
    1. Peeters M, Price T. Biologic therapies in the metastatic colorectal cancer treatment continuum - Applying current evidence to clinical practice. Cancer Treat Rev. 2012;38(5):397–406. doi: 10.1016/j.ctrv.2011.08.002.
    1. Ceelen WP. Current management of peritoneal carcinomatosis from colorectal cancer. Minerva Chir.2013;68(1):77–86.
    1. Koppe MJ, Boerman OC, Oyen WJG, Bleichrodt RP. Peritoneal carcinomatosis of colorectal origin - Incidence and current treatment strategies. Ann Surg. 2006;243(2):212–222. doi: 10.1097/01.sla.0000197702.46394.16.
    1. Segelman J, Granath F, Holm T, Machado M, Mahteme H, Martling A. Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer. Br J Surgery. 2012;99(5):699–705. doi: 10.1002/bjs.8679.
    1. Lemmens VE, Klaver YL, Verwaal VJ, Rutten HJ, Coebergh JWW, de Hingh IH. Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: a population-based study. Int J Cancer. 2011;128(11):2717–2725. doi: 10.1002/ijc.25596.
    1. Tran B, Kopetz S, Tie J, Gibbs P, Jiang Z-Q, Lieu CH, et al. Impact of BRAF Mutation and Microsatellite Instability on the Pattern of Metastatic Spread and Prognosis in Metastatic Colorectal Cancer. Cancer. 2011;117(20):4623–4632. doi: 10.1002/cncr.26086.
    1. Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J, et al. Peritoneal carcinomatosis from non-gynecologic malignancies - Results of the EVOCAPE 1 multicentric prospective study. Cancer. 2000;88(2):358–363. doi: 10.1002/(SICI)1097-0142(20000115)88:2<358::AID-CNCR16>;2-O.
    1. Pelz JOW, Chua TC, Esquivel J, Stojadinovic A, Doerfer J, Morris DL, et al. Evaluation of Best Supportive Care and Systemic Chemotherapy as Treatment Stratified according to the retrospective Peritoneal Surface Disease Severity Score (PSDSS) for Peritoneal Carcinomatosis of Colorectal Origin. BMC Cancer. 2010;10.
    1. Klaver YL, Simkens LH, Lemmens VE, Koopman M, Teerenstra S, Bleichrodt RP, et al. Outcomes of colorectal cancer patients with peritoneal carcinomatosis treated with chemotherapy with and without targeted therapy. Eur J Surg Oncol. 2012;38(7):617–623. doi: 10.1016/j.ejso.2012.03.008.
    1. Franko J, Shi Q, Goldman CD, Pockaj BA, Nelson GD, Goldberg RM, et al. Treatment of Colorectal Peritoneal Carcinomatosis With Systemic Chemotherapy: A Pooled Analysis of North Central Cancer Treatment Group Phase III Trials N9741 and N9841. J Clin Oncol. 2012;30(3):263–267. doi: 10.1200/JCO.2011.37.1039.
    1. Euler J, Prieschi A, Wenzl J, Sauerman G, Klockler K, Kretschm G. Hyperthermic peritoneal perfusion in ascites tumors in rats. Wien Klin Wochenschr. 1974;86(8):220–225.
    1. Spratt JS, Adcock RA, Muskovin M, Sherrill W, Mckeown J. Clinical Delivery System for Intra-Peritoneal Hyperthermic Chemotherapy. Cancer Res. 1980;40(2):256–260.
    1. Hildebrandt B, Wust P, Ahlers O, Dieing A, Sreenivasa G, Kerner T, et al. The cellular and molecular basis of hyperthermia. Critical Reviews in Oncology Hematology. 2002;43(1):33–56. doi: 10.1016/S1040-8428(01)00179-2.
    1. Raaphorst GP, Yang DP. The evaluation of thermal cisplatin sensitization in normal and XP human cells using mild hyperthermia at 40 and 41 degrees C. Anticancer Res. 2005;25(4):2649–2653.
    1. Los G, Sminia P, Wondergem J, Mutsaers PHA, Havemen J, Huinink DT, et al. Optimization of Intraperitoneal Cisplatin Therapy with Regional Hyperthermia in Rats. Eur J Cancer. 1991;27(4):472–477. doi: 10.1016/0277-5379(91)90389-U.
    1. Verwaal VJ, van Ruth S, de Bree E, van Slooten GW, van Tinteren H, Boot H, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21(20):3737–3743. doi: 10.1200/JCO.2003.04.187.
    1. Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H. 8-year follow-up of randomized trial: Cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2008;15(9):2426–2432. doi: 10.1245/s10434-008-9966-2.
    1. Glehen O, Kwiatkowski F, Sugarbaker PH, Elias D, Levine EA, De Simone M, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: A multi-institutional study. J Clin Oncol. 2004;22(16):3284–3292. doi: 10.1200/JCO.2004.10.012.
    1. Yan TD, Black D, Savady R, Sugarbaker PH. Systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma. J Clin Oncol. 2006;24(24):4011–4019. doi: 10.1200/JCO.2006.07.1142.
    1. Hompes D, D'Hoore A, Van Cutsem E, Fieuws S, Ceelen W, Peeters M, et al. The Treatment of Peritoneal Carcinomatosis of Colorectal Cancer with Complete Cytoreductive Surgery and Hyperthermic Intraperitoneal Peroperative Chemotherapy (HIPEC) with Oxaliplatin: A Belgian Multicentre Prospective Phase II Clinical Study. Ann Surg Oncol. 2012;19(7):2186–2194. doi: 10.1245/s10434-012-2264-z.
    1. Cavaliere F, De Simone M, Virzi S, Deraco M, Rossi CR, Garofalo A, et al. Prognostic factors and oncologic outcome in 146 patients with colorectal peritoneal carcinomatosis treated with cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy: Italian multicenter study S.I.T.I.L.O. EJSO. 2011;37(2):148–154. doi: 10.1016/j.ejso.2010.10.014.
    1. Tamsma JT, Keizer HJ, Meinders AE. Pathogenesis of malignant ascites: Starling's law of capillary hemodynamics revisited. Ann Oncol. 2001;12(10):1353–1357. doi: 10.1023/A:1012504904713.
    1. Welch S, Spithoff K, Rumble RB, Maroun J. Gastrointestinal Canc Dis Site G: Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review. Ann Oncol. 2010;21(6):1152–1162. doi: 10.1093/annonc/mdp533.
    1. Olsen MWB, Ley CD, Junker N, Hansen AJ, Lund EL, Kristjansen PEG. Angiopoietin-4 inhibits angiogenesis and reduces interstitial fluid pressure. Neoplasia. 2006;8(5):364–372. doi: 10.1593/neo.06127.
    1. Nakahara T, Norberg SM, Shalinsky DR, Hu-Lowe DD, McDonald DM. Effect of inhibition of vascular endothelial growth factor signaling on distribution of extravasated antibodies in tumors. Cancer Res. 2006;66(3):1434–1445. doi: 10.1158/0008-5472.CAN-05-0923.
    1. Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med. 2004;10(2):145–147. doi: 10.1038/nm988.
    1. Kobold S, Hegewisch-Becker S, Oechsle K, Jordan K, Bokemeyer C, Atanackovic D. Intraperitoneal VEGF Inhibition Using Bevacizumab: A Potential Approach for the Symptomatic Treatment of Malignant Ascites? Oncologist. 2009;14(12):1242–1251. doi: 10.1634/theoncologist.2009-0109.
    1. Hamilton CA, Maxwell GL, Chemofsky MR, Bernstein SA, Farley JH, Rose GS. Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer. Gynecol Oncol. 2008;111(3):530–532. doi: 10.1016/j.ygyno.2008.04.028.
    1. Bellati F, Napoletano C, Ruscito I, Pastore M, Pernice M, Antonilli M, et al. Complete remission of ovarian cancer induced intractable malignant ascites with intraperitoneal bevacizumab. Immunological observations and a literature review. Invest New Drugs. 2010;28(6):887–894. doi: 10.1007/s10637-009-9351-4.
    1. Yagi Y, Fushida S, Harada S, Tsukada T, Kinoshita J, Oyama K, et al. Biodistribution of humanized anti-VEGF monoclonal antibody/bevacizumab on peritoneal metastatic models with subcutaneous xenograft of gastric cancer in mice. Cancer Chemother Pharmacol. 2010;66(4):745–753. doi: 10.1007/s00280-009-1219-y.
    1. Passot G, Bakrin N, Garnier L, Roux A, Vaudoyer D, Wallet F, et al. Intraperitoneal vascular endothelial growth factor burden in peritoneal surface malignancies treated with curative intent: The first step before intraperitoneal anti-vascular endothelial growth factor treatment? Eur J Cancer. 2014;50(4):722–730. doi: 10.1016/j.ejca.2013.11.005.
    1. Klinger M, Tamandl D, Eipeldauer S, Hacker S, Herberger B, Kaczirek K, et al. Bevacizumab Improves Pathological Response of Colorectal Cancer Liver Metastases Treated with XELOX/FOLFOX. Ann Surg Oncol. 2010;17(8):2059–2065. doi: 10.1245/s10434-010-0972-9.
    1. Ceelen W, Van Nieuwenhove Y, Vande Putte D, Pattyn P. Neoadjuvant Chemotherapy with Bevacizumab May Improve Outcome after Cytoreduction and Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) for Colorectal Carcinomatosis. Ann Surg Oncol. 2014;21(9):3023–3028. doi: 10.1245/s10434-014-3713-7.
    1. Gremonprez F, Descamps B, Izmer A, Vanhove C, Vanhaecke F, De Wever O, et al. Pretreatment with VEGF(R)-inhibitors reduces interstitial fluid pressure, increases intraperitoneal chemotherapy drug penetration, and impedes tumor growth in a mouse colorectal carcinomatosis model. Oncotarget. 2015 Oct 6;6(30):29889-900.
    1. Eveno C, Passot G, Goere D, Soyer P, Gayat E, Glehen O, et al. Bevacizumab Doubles the Early Postoperative Complication Rate after Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Carcinomatosis of Colorectal Origin. Ann Surg Oncol. 2014;21(6):1792–1800. doi: 10.1245/s10434-013-3442-3.
    1. Hompes D, Ruers T. Review: Incidence and clinical significance of Bevacizumab-related non-surgical and surgical serious adverse events in metastatic colorectal cancer. EJSO. 2011;37(9):737–746. doi: 10.1016/j.ejso.2011.06.004.
    1. Dindo D, Demartines N, Clavien PA. Classification of surgical complications - A new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–213. doi: 10.1097/.
    1. Sugarbaker PH. Peritoneal surface oncology: review of a personal experience with colorectal and appendiceal malignancy. Tech Coloproctol. 2005;9(2):95–103. doi: 10.1007/s10151-005-0205-6.
    1. Schwartz LH, Bogaerts J, Ford R, Shankar L, Therasse P, Gwyther S, et al. Evaluation of lymph nodes with RECIST 1.1. Eur J Cancer. 2009;45(2):261–267. doi: 10.1016/j.ejca.2008.10.028.
    1. Younan R, Kusamura S, Baratti D, Cloutier A-S, Deraco M. Morbidity, toxicity, and mortality classification systems in the local regional treatment of peritoneal surface malignancy. J Surg Oncol. 2008;98(4):253–257. doi: 10.1002/jso.21057.
    1. Glehen O, Gilly FN. Quantitative prognostic indicators of peritoneal surface malignancy: carcinomatosis, sarcomatosis, and peritoneal mesothelioma. Surg Oncol Clin N Am. 2003;12(3):649–671. doi: 10.1016/S1055-3207(03)00037-1.
    1. Rubbia-Brandt L, Giostra E, Brezault C, Roth AD, Andres A, Audard V, et al. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Ann Oncol. 2007;18(2):299–304. doi: 10.1093/annonc/mdl386.
    1. Loupakis F, Schirripa M, Caparello C, Funel N, Pollina L, Vasile E, et al. Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab. Br J Cancer. 2013;108(12):2549–2556. doi: 10.1038/bjc.2013.245.
    1. Chua TC, Moran BJ, Sugarbaker PH, Levine EA, Glehen O, Gilly FN, et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol. 2012;30(20):2449–2456. doi: 10.1200/JCO.2011.39.7166.
    1. Braam HJ, van Oudheusden TR, de Hingh IH, Nienhuijs SW, Boerma D, Wiezer MJ, et al. Patterns of recurrence following complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. J Surg Oncol. 2014.
    1. Kerscher AG, Chua TC, Gasser M, Maeder U, Kunzmann V, Isbert C, et al. Impact of peritoneal carcinomatosis in the disease history of colorectal cancer management: a longitudinal experience of 2406 patients over two decades. Br J Cancer. 2013;108(7):1432–1439. doi: 10.1038/bjc.2013.82.
    1. Passot G, You B, Boschetti G, Fontaine J, Isaac S, Decullier E, et al. Pathological Response to Neoadjuvant Chemotherapy: A New Prognosis Tool for the Curative Management of Peritoneal Colorectal Carcinomatosis. Ann Surg Oncol. 2014;21(8):2608–2614. doi: 10.1245/s10434-014-3647-0.
    1. Gremonprez F, Willaert W, Ceelen W. Intraperitoneal chemotherapy (IPC) for peritoneal carcinomatosis: review of animal models. J Surg Oncol. 2014 Feb;109(2):110-6.
    1. Wong R, Cunningham D, Barbachano Y, Saffery C, Valle J, Hickish T, et al. A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection. Ann Oncol. 2011;22(9):2042–2048. doi: 10.1093/annonc/mdq714.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する